CLX 006
Alternative Names: CLX-006Latest Information Update: 04 Jul 2023
At a glance
- Originator CytosinLab Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Protein-arginine N-methyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Non-small cell lung cancer; Pancreatic cancer; Squamous cell cancer
Most Recent Events
- 19 Jun 2023 Preclinical trials in Non-small cell lung cancer in China (unspecified route) (CytosinLab Therapeutics pipeline, June 2023)
- 19 Jun 2023 Preclinical trials in Pancreatic cancer in China (unspecified route) (CytosinLab Therapeutics pipeline, June 2023)
- 19 Jun 2023 Preclinical trials in Squamous cell cancer in China (unspecified route) (CytosinLab Therapeutics pipeline, June 2023)